Melco Resorts and Enter 株価情報 (NASDAQ: MLCO)

Melco Resorts and Enter (NASDAQ:MLCO) 株価情報

Melco Resorts and Enter

Melco Resorts & Entertainment is one of only six licensed casino operators in Macao. It operates Altira, a complex focused on premium customers; City of Dreams, an integrated resort in Cotai serving both mass-market and premium patrons; and Mocha Clubs electronic gaming machines. The company also has a majority interest in Studio City, which opened in 2015. Outside Macao, Melco owns City of Dreams Manila in the Philippines and City of Dreams Mediterranean in Cyprus. The business mix in terms of adjusted EBITDA was about 82.5% from Macao with the rest largely from the Philippines as of first-half 2024.

Melco Resorts & Entertainment Limited - American Depositary Shares

Melco Resorts and Entertainment Ltd

WIIM

IBRX

ImmuniyBio shares are trading higher after the company announced it received FDA RMAT Designation for ANKTIVA(R) and CAR-NK.

LOGI

Logitech shares are trading lower after BOA downgraded its rating on the stock from neutral to underperform and its price target from $105 to $90.

As previously disclosed, on August 21, 2024, Liquidia Corporation, a Delaware corporation (the "Company") filed a lawsuit in the U.S. District Court of the District of Columbia (the "District Court") (Case No. 1:24-cv-02428)&nbsp;to challenge the decision by the U.S. Food and Drug Administration (the "FDA") to grant 3-year new clinical investigation exclusivity ("regulatory exclusivity") to Tyvaso DPI (the "FDA Litigation"). The District Court granted the parties' motion for an expedited summary judgment briefing schedule, and a summary judgment hearing was held on December 5, 2024.&nbsp; On February 27, 2025, the District Court issued a decision denying the Company's motion for summary judgment and simultaneously granting the motions for summary judgment filed by the FDA and United Therapeutics Corporation ("United Therapeutics").&nbsp; In so doing, the District Court affirmed the FDA's award of regulatory exclusivity to Tyvaso DPI.&nbsp; This decision does not affect the expiration of the regulatory exclusivity, which will still occur on May 23, 2025.
&nbsp;
United Therapeutics also filed a cross claim in the FDA Litigation, re-asserting its challenge to FDA's acceptance of the Company's amended New Drug Application ("NDA") for review.&nbsp; The Company intervened and became a party with respect to the cross claim on November 5, 2024.&nbsp; Both the Company and the FDA filed motions to dismiss United Therapeutics' cross claim.&nbsp; Those motions remain pending with the District Court and are unaffected by the decision issued by the District Court on February 27, 2025.

Biotech

News

Legal

General

LQDA

Liquidia Litigation Against FDA Over Tyvaso DPI Exclusivity Denied; United Therapeutics' Cross Claim Remains Pending; Exclusivity Expires May 23, 2025

APLS

Apellis Pharmaceuticals shares are trading higher after the company reported better-than-expected Q4 financial results.

Piper Sandler analyst Brian Mullan upgrades Cava Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAVA#NYSE">CAVA</a>) from Neutral to Overweight and lowers the price target from $142 to $115.

Upgrades

Price Target

Analyst Ratings

CAVA

Piper Sandler Upgrades Cava Group to Overweight, Lowers Price Target to $115

RXRX

Recursion Pharmaceuticals shares are trading lower following worse-than-expected Q4 financial results.

SOLV

Solventum shares are trading lower. The company reported Q4 financial results.

Trump Media &amp; Technology Group Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>) <a href="https://www.benzinga.com/quote/DJT/news">stock has been in a free fall</a>, trading at a staggering 70% discount from its 52-week high of $79.38, reached on March 26, 2024.
Closing at $23.80 on Thursday, DJT stock is deep in the red for 2025, down 30% year-to-date and struggling to find support amid persistent selling pressure.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent022825&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="629" height="490" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/28064209/Screenshot-2025-02-28-at-5.11.56-PM.png" alt="" class="wp-image-803455" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/28064209/Screenshot-2025-02-28-at-5.11.56-PM.png 629w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/28064209/Screenshot-2025-02-28-at-5.11.56-PM-300x234.png 300w" sizes="(max-width: 629px) 100vw, 629px" /></a></figure>
<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent022825&amp;t=be2bearmibe3na1">Chart created using Benzinga Pro</a>
Read Also: <a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43562195/trump-media-to-launch-bitcoin-etf-could-political-themes-undermine-long-term-stability">Trump Media To Launch Bitcoin ETF: Could Political Themes Undermine Long-Term Stability?</a>
<h2 class="wp-block-heading">A Bearish Trend With No Breaks</h2>
On the charts, DJT stock is flashing bright red signals. DJT stock is trading below its eight, 20, 50 and 200-day moving averages, reinforcing the bearish momentum. 
The eight-day simple moving average (SMA) at $26.27, the 20-day SMA at $29.10, and the 50-day SMA at $33.08 all point to continued weakness.
With the 200-day SMA at $31.39, DJT remains in a firm downtrend, showing no signs of immediate reversal.
<h2 class="wp-block-heading">From Meme Hype To Market Reality</h2>
Despite early enthusiasm surrounding its SPAC merger, Trump Media is now grappling with harsh market realities. This remains a highly speculative play until the stock finds a floor and shows signs of stability. 
At 70% off its peak, DJT may look like a bargain to some, but the technicals scream caution. <a href="https://www.benzinga.com/quote/DJT/earnings">The company reported </a>a net loss of $400.9 million, largely driven by stock-based compensation and derivative liabilities, while annual revenue dropped 12% to just $3.6 million.
To counter its financial struggles, Trump Media is pushing into fintech, launching Truth+ streaming, and selling Trump-branded products—but so far, investors aren't buying the turnaround story.
<h2 class="wp-block-heading">Florida Reincorporation</h2>
In a bid to cut costs and shield itself from legal risks, Trump Media may have <a href="https://www.bizjournals.com/tampabay/news/2025/02/26/trump-media-reincorporation-florida.html">plans</a> to reincorporate in Florida. The move promises tax breaks and a friendlier regulatory environment, but with DJT's stock price in free fall, it remains to be seen whether this shift will be enough to restore investor confidence.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43888652/trump-medias-strategic-fund-set-to-fuel-mergers-and-acquisitions">Trump Media&#8217;s Strategic Fund Set To Fuel Mergers And Acquisitions: Details</a></li>
</ul>
Image: Shutterstock

Social Media

Technicals

Tech

Trading Ideas

Trump Media Stock Craters 70% From Highs: Is There Any Floor Left?

The positive opinion is based on results from the Phase 3 BRUIN CLL-321 trial, recently presented at the 2024 American Society of Hematology Annual Meeting&nbsp;
BRUIN CLL-321 is the first randomized Phase 3 study in CLL ever conducted exclusively in patients previously treated with a BTK inhibitor
INDIANAPOLIS, Feb. 28, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jaypirca (pirtobrutinib), a non-covalent (reversible) Bruton's tyrosine kinase (BTK) inhibitor,&nbsp;for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) who have been previously treated with a BTK inhibitor.

Lilly's Jaypirca Recommended By CHMP For Approval In The EU For Adults With Relapsed Or Refractory Chronic Lymphocytic Leukemia Previously Treated With A BTK Inhibitor

Bio-Techne's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TECH#NYSE">TECH</a>) short percent of float has risen 29.12% since its last report. The company recently reported that it has 5.08 million shares sold short, which is 3.68% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.66 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Bio-Techne Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740748526_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Bio-Techne has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Bio-Techne's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Bio-Techne's peer group average for short interest as a percentage of float is 5.67%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

TECH

Is the Market Bullish or Bearish on Bio-Techne?

Webster Finl's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WBS#NYSE">WBS</a>) short percent of float has risen 5.91% since its last report. The company recently reported that it has 3.26 million shares sold short, which is 2.15% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.04 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Webster Finl Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740748522_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Webster Finl has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Webster Finl's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Webster Finl's peer group average for short interest as a percentage of float is 3.56%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Is the Market Bullish or Bearish on Webster Finl?

JPMorgan Chase's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) short percent of float has risen 7.77% since its last report. The company recently reported that it has 31.01 million shares sold short, which is 1.11% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.4 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>JPMorgan Chase Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740748516_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for JPMorgan Chase has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing JPMorgan Chase's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, JPMorgan Chase's peer group average for short interest as a percentage of float is 1.16%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Peering Into JPMorgan Chase's Recent Short Interest

Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) CEO Jensen Huang might be all-in on GPUs, but IonQ Inc's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IONQ#NYSE">IONQ</a>) CEO Niccolo De Masi <a href="https://www.benzinga.com/topic/quantum-computing">says quantum computing</a> is the next big thing—and he's not backing down.
<h2 class="wp-block-heading">Quantum: The Third Leg Of Computing</h2>
"I can remember 10 years ago when Intel was busy bashing Jensen and Nvidia and saying GPUs would never matter," De Masi <a href="https://www.cnbc.com/video/2025/02/27/ionq-ceo-on-quantum-computing-and-mechanics-ai.html">said</a> in a CNBC interview. "I find that ironic that our market cap is about the same as Nvidia's 10 years ago. Now, Jensen is saying that you don't matter."
IonQ stock may have had a rocky 2025—down 42% year-to-date—but over the past six months, the stock has skyrocketed 257.9%, signaling that investors are taking the quantum race seriously. 
De Masi is confident that quantum processing units (QPUs) will soon sit alongside CPUs and GPUs as the backbone of computing.
Read Also: <a href="https://www.benzinga.com/news/management/25/02/43993251/ionq-q4-eps-miss-500-million-offering-ceo-appointment-acquires-stake-in-id-quantique-details">IonQ Q4 EPS Miss, $500 Million Offering, CEO Appointment, Acquires Stake In ID Quantique: Details</a>
<h2 class="wp-block-heading">Revenue, Partnerships, Quantum's Real-World Impact</h2>
&#8220;Quantum computing needs a lot of qubits to be truly useful. We think it takes about that many to do this useful stuff that we're already driving GAAP revenue around this year." De Masi said. "We're the only company in the space that has guided to $85 million in GAAP revenue this year at the midpoint."
IonQ isn't just talking the talk, it. is securing major partnerships with industry giants like Microsoft Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), AstraZeneca Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) and General Dynamics Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GD#NYSE">GD</a>).
"We're going to solve problems that no one else can solve in the world because of the beauty of quantum mechanics," De Masi said.
<h2 class="wp-block-heading">The 800-Pound Gorilla In Quantum Computing</h2>
With Nvidia dominating AI and Microsoft making heavy bets on quantum through Azure, IonQ is positioning itself as the independent leader in quantum computing. "We were the first. We were the best capitalized independent player in the market," De Masi stated. "I would argue that we remain the 800-pound gorilla of the category."
As tech giants continue to evolve their computing stacks, the question isn't whether quantum computing matters, it's when it will become indispensable. And IonQ is betting that moment is sooner than most expect.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/tech/25/02/44032246/sam-altman-calls-it-magic-as-openai-rolls-out-gpt-4-5-feels-like-talking-to-a-thoughtful-person-to-me">Sam Altman Calls It &#8216;Magic&#8217; As OpenAI Rolls Out GPT-4.5: &#8216;Feels Like Talking To A Thoughtful Person To Me&#8217;</a></li>
</ul>
Photo: Shutterstock

Long Ideas

Interview

IONQ

MSFT

NVDA

IonQ CEO Fires Back At Nvidia's Jensen Huang: 'We Remain The 800 Pound Guerrilla'

HLXB

Trading Halt: Halt status updated at 8:15:00 AM ET: Quotation Resumption: News and Resumption Times

Rosenblatt analyst Mike Genovese maintains Adtran Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADTN#NASDAQ">ADTN</a>) with a Buy and maintains $15 price target.

ADTN

Rosenblatt Maintains Buy on Adtran Holdings, Maintains $15 Price Target

Morgan Stanley analyst Erik Woodring maintains HP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPQ#NYSE">HPQ</a>) with a Equal-Weight and lowers the price target from $36 to $35.

Morgan Stanley Maintains Equal-Weight on HP, Lowers Price Target to $35

Small Cap Consumer Research analyst Eric Beder reiterates Betterware de Mexico SAPI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BWMX#NYSE">BWMX</a>) with a Buy and maintains $22.5 price target.

Reiteration

BWMX

Small Cap Consumer Research Reiterates Buy on Betterware de Mexico SAPI, Maintains $22.5 Price Target

Morgan Stanley analyst Keith Weiss maintains Autodesk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADSK#NASDAQ">ADSK</a>) with a Overweight and raises the price target from $375 to $385.

ADSK

Morgan Stanley Maintains Overweight on Autodesk, Raises Price Target to $385

Frontline Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FRO#NYSE">FRO</a>) reported <a target="_blank" href="https://www.frontlineplc.cy/fro-fourth-quarter-and-full-year-2024-results/" rel="noreferrer noopener">fourth-quarter</a> revenue growth of 6.9% year-over-year to $443.491 million, surpassing the $300.67 million consensus.
Adjusted EPS for the quarter declined to 20 cents from 46 cents a year ago, <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">missing the consensus of 36 cents.</a>
Reported spot TCEs for VLCCs, Suezmax tankers, and LR2/Aframax tankers were $35,900 (vs. $39,200 last year), $33,300 (vs. $45,700 last year) and $26,100&nbsp;(vs. $42,900 prior year) per day.
At the close of the fourth quarter of 2024, contracted ballast days totaled 1,116 for VLCCs, 238 for Suezmax tankers, and 174 for LR2/Aframax tankers.
Net operating income for the quarter declined to $129.72 million from $138.05 million a year ago, and margin contracted 400 bps to 29.3%.
Operating cash flow was $167.85 million in the fourth quarter, compared to $100.49 million in the same quarter a year ago. For 2024, it stood at $736.41 million, down from $856.18 million a year ago. Frontline held cash and cash equivalents of $413.53 million as of the quarter end.
The Board declared a $0.20 per share dividend for the fourth quarter, with a record date of March 14, 2025, ex-dividend dates of March 13 (Oslo) and March 14 (NYSE), and payment on March 31, 2025.
As of December 31, 2024, the Company owned a fleet of 81 vessels, including 41 VLCCs, 22 Suezmax tankers, and 18 LR2/Aframax tankers, with a total capacity of approximately 17.8 million DWT.
"The fourth quarter of 2024 came in unusually soft compared to previous years. Global oil demand was up marginally as the year came to an end, but global seaborne exports slowed in the fourth quarter. During the quarter we saw positive developments in the enforcement of sanctions against Iran and Russia in particular, but we could not escape the fact that these two countries represent a material part of the supply to Asia, at cost to demand for the vessels Frontline operates," commented Lars H. Barstad, Chief Executive Officer of Frontline Management.
"For 2025 we have already seen broader sanctions with a wider scope, at the same time as key importers of exposed crude are diversifying away from the mentioned suppliers. Compliant fleet growth for the asset classes we deploy peaked a few years back, making the outlook very constructive as Frontline sail into the new year with our cost-efficient operations and modern fleet," added Barstad.
Outlook: Frontline expects spot TCEs for the first quarter of 2025 to be lower than the currently contracted rates, primarily due to the impact of ballast days.
Price Action: FRO shares traded higher by 1.05% at $15.47 premarket at last check Friday.

Earnings

Equities

Movers

Frontline Q4 Earnings: Revenue Beats, But EPS Sinks—CEO Cites 'Unusually Soft' Market

Morgan Stanley analyst Jorge Kuri downgrades DLocal (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLO#NASDAQ">DLO</a>) from Overweight to Equal-Weight and lowers the price target from $11 to $10.

Downgrades

Morgan Stanley Downgrades DLocal to Equal-Weight, Lowers Price Target to $10

Press Releases

Melco Announces Unaudited Third Quarter 2024 Earnings

Studio City International Holdings Limited Announces Unaudited Third Quarter 2024 Earnings

Financing

Studio City Enters into Senior Facilities Agreement

Travel

Melco leads with the most Five-Star awards in Macau and Asia in the 2025 Forbes Travel Guide

Melco earns global recognition for corporate sustainability

Melco Announces Earnings Release Date

Studio City Announces Earnings Release Date

Contracts

Melco Announces Exploration of Strategic Alternatives in Relation to City of Dreams Manila

Melco Announces Unaudited Fourth Quarter 2024 Earnings

Studio City International Holdings Limited Announces Unaudited Fourth Quarter 2024 Earnings

MLCO

Accel Entertainment

PlayAGS

Ballys

Boyd Gaming

Codere Online Luxembourg, S.A. - Ordinary Shares

Codere Online Luxembourg

Churchill Downs, Incorporated - Common Stock

Churchill Downs

Canterbury Park Holding Corporation - Common Stock

Canterbury Park Holding

Caesars Entertainment, Inc. - Common Stock

Caesars Entertainment

DraftKings

Everi Hldgs

Full House Resorts

Golden Entertainment, Inc. - Common Stock

Golden Entertainment

Genius Sports

International Game Technology Ordinary Shares

Intl Game Tech

Inspired Entertainment, Inc. - Common Stock

Inspired Entertainment

Light & Wonder

Las Vegas Sands

Monarch Casino & Resort, Inc. - Common Stock

Monarch Casino & Resort

MGM Resorts International

Studio City International Holdings Limited American depositary shares, each representing four Class A ordinary shares

Comments

Melco Resorts and Enter

ニュース

パートナーシップ

ベンジンガ・グローバル